NCT00796250终止3 期
Efficacy of Infliximab as "Bridging Therapy" in the Treatment of Patients Affected by Corticodependent Crohn's Disease Under Standard Treatment With Azathioprine
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 9
- 主要终点
- To evaluate the therapeutic efficacy of repeated infliximab infusions in order to maintain Crohn's disease remission (Crohn's disease Activity Index [CDAI] <=150) at the end of the study.
研究概览
简要总结
This is a double-blind, double-dummy, prednisolone-controlled, multi-center, randomized, parallel-group clinical study to evaluate the therapeutic efficacy of repeated infliximab infusions in order to maintain Crohn's disease remission at the end of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and Female patients with age between 18 and 65 years.
- •Patients suffering from corticodependent Crohn's disease, in reheightening phase, with CDAI value >=
- •Patients able to participate and to comply with the study.
- •Patients with adequate bone marrow stock: GB >=3.5x109/L, PLTs >=100 x 103, Hb >=9 gr/dL.
- •Patients able and willing to give written informed consent.
排除标准
- •Patients with abscesses or active perianal diseases.
- •Clinically symptomatic and/or with retrodilatation intestinal stenosis.
- •Patients previously treated with infliximab.
- •Patients with history of allergy to murine proteins.
- •Treatment with immunosuppressant such as AZA, 6-mercaptopurine, methotrexate and cyclosporine A during the previous 3 months.
- •Positive feces exams for intestinal pathogens, parasitic or toxin of clostridium difficilis.
- •Tuberculosis (TBC) both active and inactive, evaluated by means of a detailed description (personal history of tuberculosis or possible previous contact with a source of TBC infection), and appropriate screening tests, Thorax Rx, tuberculin test.
- •Presence of severe infections such as hepatitis, pneumonia, pyelonephritis within the past 3 months before the enrolment. Less severe infections, such as those in charge of the upper respiratory tract (cold syndrome), are not considered exclusion criteria as well as the uncomplicated urinary tract infections, contracted during the previous 3 months before study inclusion.
- •Ongoing infections due to CMV, pneumocystis carinii, atypical mycobacterium. Proved HIV infection, presence of ARC or AIDS.
- •Necessity during the study of elective or emergency surgical operation.
- •Altered hepatic function: total bilirubin >=1.5 times the upper limit of the normal ranges (UNL), AST (SGOT) >=2 UNL, phosphatase alkaline >=2.5 UNL, or PTT - INR >=1.5 UNL.
- •Altered renal function: creatinine >=1.5 mg.
- •Presence of serious concomitant illnesses (cardiac, pulmonary, neurological diseases).
- •History of pathology in charge of the haemopoietic system and of lymphoproliferative diseases such as lymphoma, lymphadenopathies of unusual localisation (i.e. at the nape, epitochlear or periaortic) or splenomegaly.
- •Presence of neoplastic or pre-neoplastic lesions, or history of neoplasm in the past 5 years.
- •Presence or history of drug or alcohol abuse.
- •Pregnant or lactating women.
- •Women of childbearing potential without adequate contraception except in case of surgical menopause. These methods of birth control should also be used during the 6 months after the last infusion.
- •Contraindications for AZA (i.e. lymphoproliferative diseases, leukopenia) and prednisolone (i.e. peptic ulcer, systemic fungal infections) as laid out in the summary of product characteristics.
- •Hyperamylasemia >=1.5 times the upper limit of the normal ranges.
研究组 & 干预措施
Group A
Experimental
干预措施: Infliximab (Biological)
Group A
Experimental
干预措施: AZA (Drug)
Group A
Experimental
干预措施: Placebo Prednisolone (Drug)
Group B
Active Comparator
干预措施: Prednisolone (Drug)
Group B
Active Comparator
干预措施: AZA (Drug)
Group B
Active Comparator
干预措施: Placebo Infliximab (Biological)
结局指标
主要结局
To evaluate the therapeutic efficacy of repeated infliximab infusions in order to maintain Crohn's disease remission (Crohn's disease Activity Index [CDAI] <=150) at the end of the study.
时间窗: Week 30
次要结局
- Tolerability evaluation (labs parameters, vital signs, adverse events).(At each visit.)
- Quality of life assessment, by IBDQ questionnaire.(Baseline, Week 10, and Week 30.)
研究者
相似试验
已完成
2 期
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related CachexiaCachexiaPancreatic NeoplasmsNCT00060502Centocor, Inc.73
已完成
3 期
A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type PsoriasisPsoriasisNCT01177800Xian-Janssen Pharmaceutical Ltd.129
已完成
不适用
Efficacy of Infliximab as a second Bio in patients with refractory rheumatoid arthritisRheumatoid arthritisJPRN-UMIN000020799Hokkaido University Hospital, Medicine II30
终止
2 期
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell ArteritisGiant Cell ArteritisNCT00076726Centocor, Inc.44
已完成
3 期
A Study of the Safety and Efficacy of Infliximab in Patients With PsoriasisPsoriasisNCT00106834Centocor, Inc.378